7 reasons why you should use donepezil with memantine Review article
Article Sidebar
Published:
Jun 30, 2016
Keywords:
Alzheimer’s disease, symptomatic treatment, donepezil, memantine
Main Article Content
Abstract
Alzheimer’s disease is chronic, neurodegenerative disease with unknown pathomechanisms. There is lack of preventive, efficient treatment, therefore concentration on symptomatic treatment is directed. We have four procognitive drugs: donepezil, rivastigmine, galantamine and memantine, which are influencing cholinergic and glutamatergic systems. Results of research confirmed that efficacy and safety in combined treatment of donepezil, and memantine is higher, improving cognitive functions, psychopathological symptoms and behavioural disturbances.
Article Details
How to Cite
Parnowski , T. (2016). 7 reasons why you should use donepezil with memantine. Medycyna Faktow (J EBM), 9(2(31), 140-145. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2252
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Morris J.C., Roe C.M., Grant E.A. et al.: Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009; 66(12): 1469-1475.
2. Francis P.T., Palmer A.M., Snape M. et al.: The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999; 66: 137-147.
3. Danysz W., Parsons C.G., Möbius H.J. et al.: Neuroprotective and symptomatological Action of memantine relevant for Alzheimer’s disease – a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research 1999; 2: 85-97.
4. Cummings J.L., Isaacson A., Schmitt F.A., Velting D.M.: Practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann. Clin. Transl. Neurol. 2015; 2(3): 307-323.
5. Cummings J.L., McRae T., Zhang R.: Donepezil – Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry 2006; 14(7): 605-612.
6. Suzuki H., Inoue Y., Mikami K., Gen K.: The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer’s disease with behavioral and psychological symptoms on dementia: a preliminary open-label trial. Ther. Adv. Psychopharmacol. 2014; 4(1): 37-42.
7. Wilkinson D., Schindler R., Schwam E. et al.: Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2009; 28(3): 244-251.
8. Birks J.: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006; 25(1): CD005593. Review.
9. Gauthier S., Wirth Y., Möbius H.J.: Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 2005; 20(5): 459-464.
10. Cheewakriengkrai L., Gauthier S.A.: 10-year perspective on donepezil. Expert Opin. Pharmacother. 2013; 14(3): 331-338.
11. Atri A., Shaughnessy L.W., Locascio J.J. et al.: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008; 22(3): 209-221.
12. Lopez O.L., Becker J.T., Wahed A.S.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.J. Neurol. Neurosurg. Psychiatry 2009; 80(6): 600-607.
13. Atri A., Hendrix S.B., Pejović V. et al.: Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers. Res. Ther. 2015; 7(1): 28.
14. Matsuzono K., Hishikawa N., Ohta Y. et al.: Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. J. Alzheimers Dis. 2015; 45(3): 771-780.
15. Howard R., McShane R., Lindesay J. et al.: Donepezil and memantine for moderate to severe Alzheimer’s disease. NEJM 2012; 366(10): 893-903.
16. Rungsanpanya T., Muangpaisan W., Praditsuwan R.: Clinical practice with antidementia drugs in a geriatric clinic. J. Med. Assoc. Thai. 2012; 95(8): 1081-1089.
17. Pariente A., Sanctussy D.J., Miremont-Salamé G. et al.: l’Association Française des Centres Régionaux de Pharmacovigilance (CRPV). Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs. 2010; 24(1): 55-63.
18. European Medicines Evaluation Agency Ebixa EPAR Scientific Discussion EMEA 2006 [online].
19. Babai S., Auriche P., Le- Louët H.: Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database. Therapie 2010; 65(3): 255-259.
20. Jones R.W.: A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int. J. Geriatr. Psychiatry 2010; 25(6): 547-553.
21. Akasofu S., Kimura M., Kosasa T. et al.: Study of neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem. Biol. Interact. 2008; 175(1-3): 222-226.
22. Castaneda M.T., Lopez E.D., Touhami A. et al.: Neuroprotection of medial septal cholinergic neurons by memantine after intralateral septal injection of Aβ1-40. Neuroreport. 2015; 26(8): 450-454.
23. Malouf R., Birks J.: Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev. 2004 (1): CD004395. Review.
24. Etsuro M., Manabu I., Reiko N. et al.:. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimer’s Research & Therapy 2015; 7: 5.
25. Aarsland D., Ballard C., Rongve A. et al.: Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr. Neurol. Neurosci. Rep. 2012; 12(5): 492-501.
26. Hort J., O’Brien J.T., Gainotti G et al.: EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur. J. Neurol. 2010; 17(10): 1236-1248.
2. Francis P.T., Palmer A.M., Snape M. et al.: The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999; 66: 137-147.
3. Danysz W., Parsons C.G., Möbius H.J. et al.: Neuroprotective and symptomatological Action of memantine relevant for Alzheimer’s disease – a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research 1999; 2: 85-97.
4. Cummings J.L., Isaacson A., Schmitt F.A., Velting D.M.: Practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann. Clin. Transl. Neurol. 2015; 2(3): 307-323.
5. Cummings J.L., McRae T., Zhang R.: Donepezil – Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry 2006; 14(7): 605-612.
6. Suzuki H., Inoue Y., Mikami K., Gen K.: The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer’s disease with behavioral and psychological symptoms on dementia: a preliminary open-label trial. Ther. Adv. Psychopharmacol. 2014; 4(1): 37-42.
7. Wilkinson D., Schindler R., Schwam E. et al.: Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2009; 28(3): 244-251.
8. Birks J.: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006; 25(1): CD005593. Review.
9. Gauthier S., Wirth Y., Möbius H.J.: Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 2005; 20(5): 459-464.
10. Cheewakriengkrai L., Gauthier S.A.: 10-year perspective on donepezil. Expert Opin. Pharmacother. 2013; 14(3): 331-338.
11. Atri A., Shaughnessy L.W., Locascio J.J. et al.: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008; 22(3): 209-221.
12. Lopez O.L., Becker J.T., Wahed A.S.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.J. Neurol. Neurosurg. Psychiatry 2009; 80(6): 600-607.
13. Atri A., Hendrix S.B., Pejović V. et al.: Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers. Res. Ther. 2015; 7(1): 28.
14. Matsuzono K., Hishikawa N., Ohta Y. et al.: Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. J. Alzheimers Dis. 2015; 45(3): 771-780.
15. Howard R., McShane R., Lindesay J. et al.: Donepezil and memantine for moderate to severe Alzheimer’s disease. NEJM 2012; 366(10): 893-903.
16. Rungsanpanya T., Muangpaisan W., Praditsuwan R.: Clinical practice with antidementia drugs in a geriatric clinic. J. Med. Assoc. Thai. 2012; 95(8): 1081-1089.
17. Pariente A., Sanctussy D.J., Miremont-Salamé G. et al.: l’Association Française des Centres Régionaux de Pharmacovigilance (CRPV). Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs. 2010; 24(1): 55-63.
18. European Medicines Evaluation Agency Ebixa EPAR Scientific Discussion EMEA 2006 [online].
19. Babai S., Auriche P., Le- Louët H.: Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database. Therapie 2010; 65(3): 255-259.
20. Jones R.W.: A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int. J. Geriatr. Psychiatry 2010; 25(6): 547-553.
21. Akasofu S., Kimura M., Kosasa T. et al.: Study of neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem. Biol. Interact. 2008; 175(1-3): 222-226.
22. Castaneda M.T., Lopez E.D., Touhami A. et al.: Neuroprotection of medial septal cholinergic neurons by memantine after intralateral septal injection of Aβ1-40. Neuroreport. 2015; 26(8): 450-454.
23. Malouf R., Birks J.: Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev. 2004 (1): CD004395. Review.
24. Etsuro M., Manabu I., Reiko N. et al.:. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimer’s Research & Therapy 2015; 7: 5.
25. Aarsland D., Ballard C., Rongve A. et al.: Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr. Neurol. Neurosci. Rep. 2012; 12(5): 492-501.
26. Hort J., O’Brien J.T., Gainotti G et al.: EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur. J. Neurol. 2010; 17(10): 1236-1248.